Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Cancer immunotherapies like checkpoint blockade and chimeric antigen receptor (CAR) T cell therapy have transformed cancer treatment.
• CAR T cells are FDA-approved and highly successful for B cell malignancies such as leukemia and lymphoma.
• However, CAR T cell therapy has shown limited success against solid tumors to date.

Purpose of the Study:

• To review recent strategies aimed at enhancing CAR T cell efficacy in treating solid tumors.
• To discuss methods for overcoming the immunosuppressive tumor microenvironment to improve CAR T cell responses.

Main Methods:

• Discussion of recent advancements in CAR T cell therapy for solid tumors.
• Review of strategies targeting the tumor microenvironment, including checkpoint pathways, metabolic pathways, and cytokine production.

Main Results:

• CAR T cell therapy has revolutionized treatment for certain B cell malignancies.
• Strategies modulating the tumor microenvironment have shown considerable enhancement of adoptive T cell immunotherapy.
• Recent strategies focus on improving CAR T cell antitumor responses in solid cancers.

Conclusions:

• Enhancing CAR T cell therapy for solid tumors requires overcoming the immunosuppressive tumor microenvironment.
• Modulating the tumor microenvironment is key to improving the efficacy of CAR T cell immunotherapy against solid cancers.
• This review highlights the latest strategies to boost CAR T cell antitumor responses in solid tumors.